Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Murphy, Derek M ^a,b   Buckley, Patrick G ^a,b   Das, Sudipto ^a,b   Watters, Karen M ^a,b   Bryan, Kenneth ^a,b   Stallings, Raymond L ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; METHYL CPG BINDING PROTEIN 2; PROTEIN MYCN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; DNA; DNA BINDING PROTEIN; MECP2 PROTEIN, HUMAN; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ARTICLE; CANCER GENETICS; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NEUROBLASTOMA; PROMOTER REGION; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; BINDING SITE; BIOLOGY; CPG ISLAND; E BOX ELEMENT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEMIZYGOTE; HUMAN GENOME; METABOLISM; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BINDING SITES; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; CPG ISLANDS; DNA; DNA METHYLATION; DNA-BINDING PROTEINS; E-BOX ELEMENTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HEMIZYGOTE; HUMANS; METHYL-CPG-BINDING PROTEIN 2; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROTEIN BINDING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 79959433009     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021436     Document Type: Article

References (53)

1. Mukherjee B, Morgenbesser SD, DePinho RA, (1992) Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants. Genes Dev 6: 1480-1492.
2. Van Roy N, De Preter K, Hoebeeck J, Van Maerken T, Pattyn F, et al. (2009) The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med 1: 74.
3. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM, (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985-2995.
4. Amin C, Wagner AJ, Hay N, (1993) Sequence-specific transcriptional activation by Myc and repression by Max. Mol Cell Biol 13: 383-390.
5. Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, et al. (1997) An alternative pathway for gene regulation by Myc. EMBO J 16: 5672-5686.
6. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, et al. (2001) Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A 98: 4510-4515.
7. Kim J, Lee JH, Iyer VR, (2008) Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One 3: e1798.
8. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, et al. (2006) Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A 103: 17834-17839.
9. Murphy DM, Buckley PG, Bryan K, Das S, Alcock L, et al. (2009) Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS One 4: e8154.
10. Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, et al. (2011) Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog 50: 403-411.
11. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, et al. (2005) The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A 102: 731-736.
12. Koppen A, Ait-Aissa R, Koster J, van Sluis PG, Ora I, et al. (2007) Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. Eur J Cancer 43: 2413-2422.
13. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, et al. (2010) p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 70: 1377-1388.
14. Ochiai H, Takenobu H, Nakagawa A, Yamaguchi Y, Kimura M, et al. (2010) Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma. Oncogene 29: 2681-2690.
15. Gupta A, Williams BR, Hanash SM, Rawwas J, (2006) Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma. Cancer Res 66: 8100-8108.
16. Shohet JM, Hicks MJ, Plon SE, Burlingame SM, Stuart S, et al. (2002) Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 62: 1123-1128.
17. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, et al. (2009) Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 4: e7850.
18. Mestdagh P, Fredlund E, Pattyn F, Rihani A, Van Maerken T, et al. (2010) An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene.
19. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, et al. (2008) MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 122: 699-704.
20. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, et al. (2008) Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 3: e2236.
21. Cotterman R, Jin VX, Krig SR, Lemen JM, Wey A, et al. (2008) N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res 68: 9654-9662.
22. Berdasco M, Ropero S, Setien F, Fraga MF, Lapunzina P, et al. (2009) Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci U S A 106: 21830-21835.
23. Buckley PG, Das S, Bryan K, Watters KM, Alcock L, et al. (2010) Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int J Cancer.
24. Yang TY, Ostler KR, Chlenski A, Guerrero LJ, Salwen HR, Godley LA, Cohn SL, (2010) Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer.
25. Muotri AR, Marchetto MC, Coufal NG, Oefner R, Yeo G, et al. (2011) L1 retrotransposition in neurons is modulated by MeCP2. Nature 468: 443-446.
26. Konduri SD, Srivenugopal KS, Yanamandra N, Dinh DH, Olivero WC, et al. (2003) Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. Oncogene 22: 4509-4516.
27. Ramachandran K, Gopisetty G, Gordian E, Navarro L, Hader C, et al. (2009) Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res 69: 1527-1535.
28. Gonzales ML, LaSalle JM, (2010) The role of MeCP2 in brain development and neurodevelopmental disorders. Curr Psychiatry Rep 12: 127-134.
29. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, et al. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19: 187-191.
30. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, et al. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386-389.
31. Balmer D, Arredondo J, Samaco RC, LaSalle JM, (2002) MECP2 mutations in Rett syndrome adversely affect lymphocyte growth, but do not affect imprinted gene expression in blood or brain. Hum Genet 110: 545-552.
32. Tudor M, Akbarian S, Chen RZ, Jaenisch R, (2002) Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc Natl Acad Sci U S A 99: 15536-15541.
33. Yasui DH, Peddada S, Bieda MC, Vallero RO, Hogart A, et al. (2007) Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc Natl Acad Sci U S A 104: 19416-19421.
34. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, et al. (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320: 1224-1229.
35. Horike S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T, (2005) Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat Genet 37: 31-40.
36. Lasalle JM, Yasui DH, (2009) Evolving role of MeCP2 in Rett syndrome and autism. Epigenomics 1: 119-130.
37. Nuber UA, Kriaucionis S, Roloff TC, Guy J, Selfridge J, et al. (2005) Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome. Hum Mol Genet 14: 2247-2256.
38. Beierle EA, Trujillo A, Nagaram A, Kurenova EV, Finch R, et al. (2007) N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J Biol Chem 282: 12503-12516.
39. Beierle EA, Massoll NA, Hartwich J, Kurenova EV, Golubovskaya VM, et al. (2008) Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin Cancer Res 14: 3299-3305.
40. Lu HF, Lai KC, Hsu SC, Lin HJ, Kuo CL, et al. (2009) Involvement of matrix metalloproteinases on the inhibition of cells invasion and migration by emodin in human neuroblastoma SH-SY5Y cells. Neurochem Res 34: 1575-1583.
41. Beierle EA, Ma X, Trujillo A, Kurenova EV, Cance WG, et al. (2010) Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines. Mol Carcinog 49: 224-234.
42. Klose RJ, Sarraf SA, Schmiedeberg L, McDermott SM, Stancheva I, et al. (2005) DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol Cell 19: 667-678.
43. Li Q, Barkess G, Qian H, (2006) Chromatin looping and the probability of transcription. Trends Genet 22: 197-202.
44. Krajewski WA, Becker PB, (1998) Reconstitution of hyperacetylated, DNase I-sensitive chromatin characterized by high conformational flexibility of nucleosomal DNA. Proc Natl Acad Sci U S A 95: 1540-1545.
45. Frank SR, Parisi T, Taubert S, Fernandez P, Fuchs M, et al. (2003) MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep 4: 575-580.
46. McMahon SB, Wood MA, Cole MD, (2000) The Essential Cofactor TRRAP Recruits the Histone Acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 20: 556-562.
47. Perini G, Diolaiti D, Porro A, Della Valle G, (2005) In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation. Proc Natl Acad Sci U S A 102: 12117-12122.
48. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, et al. (2008) Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9: R150.
49. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, et al. (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305: 245-248.
50. Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, et al. (2006) High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 66: 3673-3680.
51. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, et al. (2005) Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37: 853-862.
52. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, et al. (2007) Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39: 457-466.
53. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, et al. (2009) STRING 8--a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 37: D412-416.